Strikingly, CX-5461 treatment substantially and significantly inhibited the growth rate of tumours formed from two BRCA2 deficient HCT116 cell lines (B18 and B46), in a dose-dependent manner (Fig. 8a, Supplementary Fig. 8a). Here, BRCA2 is linked to neoplasm.